Trials In Focus: Allogene Off-The-Shelf Study Mirrors Earlier CAR-T Trials

Trial Design Draws Analyst Praise

In Scrip’s new column tracking clinical trial developments, NewAmsterdam, CatalYm, Verve, Bellerophon and Almirall announced new trials or changes to existing ones, while CROs Parexel and PPD announced new programs and CTI appointed a new exec.

• Source: Shutterstock

Allogene Therapeutics Inc. drew praise from analysts with the initiation of what it called the first potentially pivotal Phase II trial of an off-the-shelf CAR-T therapy, its CD19-targeted ALLO-501A, in patients with relapsed/refractory large B-cell lymphoma (LBCL). Analysts pointed to a trial design that largely mirrors past studies of autologous CAR-T therapies for what could become the first allogeneic CAR-T to win US Food and Drug Administration approval, which allows for better comparison between ALLO-501A and its autologous counterparts, particularly Gilead Sciences, Inc.’s Yescarta (axicabtagene ciloleucel).

The company announced the initiation of the single-arm, 100-patient ALPHA2 trial on 6 October, in which patients will receive the allogeneic ALLO-501A following a lymphodepletion regimen comprising fludarabine, cyclophosphamide and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By 

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By 

One Phase III trial hits but a second study misses by a mile.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Merck & Co./Daiichi Pull Patritumab Deruxtecan BLA On Disappointing OS

 

Patritumab deruxtecan is the lead antibody drug conjugate in a $22bn deal signed between the two partners, with the decision marking a disappointing setback

More from R&D

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

 
• By 

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.